Main Menu
Untitled Page
Home > Equity > Company info > Company Snapshot
27 September 2020

Search Quotes

  Enter at least 3 characters from BSE Code for a company or the company's name

Dr Reddys Laboratories Ltd (Pharmaceuticals - Indian - Bulk Drugs & Formln)

Last Price 5,112.20
Net Changes 84.80
Volume 3514249
Prev Close 5,027.40
5,112.20 84.80 (1.69%)
Date: Sep 25,2020 EOD




Index Details Pharmaceuticals - Indian - Bulk Drugs & Formln


Chart

Stock Price Details

Market Statistics

Open Price 5130 Div Yield (%) 0.49
Buy (Size) 5,115.00(×2) Eps(Rs) 200.87
Sell (Size) 5,114.05(×3) Book Value (Stand.)(Rs) 919.75
Value 52153140500 Book Value(conso.)(Rs) 944.2174005
Buy Quantity 2 Market Cap(Rs.Cr) 85030.94
Sell Quantity 3 Face Value(Rs) 5
Today's High 5150 Market Lot 1
Today's Low 5050 AGM Date Jul
52-Week High 5514.65 Book Closure Date Jul
52-Week Low 2497.6 ISIN No. INE089A01023

Share Holding Pattern

  No Of shares % Share Holding
Total Foreign (Promoter & Group) 0 0.00
Indian (Promoter & Group) 44458528 26.74
Total of Promoter 44458528 26.74
Non Promoter (Institution) 73092566 43.97
Non Promoter (Non-Institution) 48311222 29.06
Total Non Promoter 121403788 73.03
Total Promoter & Non Promoter 165862316 99.78
Custodians(Against Depository Receipts) 370200 0.22
Grand Total 166232516 100.00

Company News

25-Sep-2020  Dr Reddys launches Dexmedetomidine Hydrochloride in 0.9% Sodiu...
Dr Reddys launches Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection

Dr Reddys Laboratories announced the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a therapeutic equivalent generic version of Precedex® (dexmedetomidine hydrochloride) in 0.9% Sodium Chloride Injection, approved by the U.S. Food and Drug Administration (USFDA).

The Precedex® in 0.9% Sodium Chloride Injection brand and generic market had U.S. sales of approximately $210 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health.

Dr. Reddy's Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection is available in 200 mcg/50 mL (4 mcg/mL) and 400 mcg/100 mL (4 mcg/mL) in 50 mL and 100 mL clear glass vials, respectively. The strength is based on the dexmedetomidine base. Containers are intended for single-dose only.

25-Sep-2020  Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited -...
Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Loss of Share Certificates

Dr. Reddys Laboratories Limited has informed the Exchange about Loss of Share Certificates
24-Sep-2020  Dr Reddys Laboratories allots 14,284 equity shares under ESOP
Dr Reddys Laboratories allots 14,284 equity shares under ESOP

Dr Reddys Laboratories has allotted 14,284 equity shares of Rs.5/- each of the Company, fully paid up, on 23 September 2020 to Employees on exercise of their Stock Options.
23-Sep-2020  Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited -...
Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - ESOP/ESOS/ESPS

Dr. Reddys Laboratories Limited has informed the Exchange regarding Allotment of 14284 Shares.
18-Sep-2020  Dr. Reddy hits record high; gains over 20% in four days'
Dr. Reddy hits record high; gains over 20% in four days'

The stock has added 20.34% in four sessions from its recent closing low of Rs 4,364.65 on 14 September 2020.

It jumped as much as 9.86% at the day's high at Rs 5302.85 today, which is a record high for the counter.

On the technical front, the stock's RSI (relative strength index) stood 79.147. The RSI oscillates between zero and 100. Traditionally the RSI is considered overbought when above 70 and oversold when below 30.

The stock is currently trading above its 50-day, 100-day and 200-day simple moving average (SMA) placed at 4391.38, 4159.49 and 3644.56, respectively.

In a BSE filing made after market hours on Thursday, Dr. Reddy's Laboratories announced that it has settled patent litigation with Celgene, a wholly-owned subsidiary of US based Bristol Myers Squibb (BMS), for Revlimid (lenalidomide) capsules.

As part of the settlement, Celgene has agreed to provide Dr Reddy's with a licence to sell volume-limited amounts of generic lenalidomide capsules in the US after March 2022 subject to regulatory approval.

Additionally, Celgene has agreed to provide Dr. Reddy's Lab with a license to its patents required to manufacture and sell an unlimited quantity of generic lenalidomide in the US beginning no earlier than 31 January 2026.

Earlier this week, the Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, and Dr Reddy's Laboratories agreed to cooperate on clinical trials and distribution of Sputnik V vaccine in India. Upon regulatory approval in India, RDIF shall supply to Dr. Reddy's 100 million doses of the vaccine. The Sputnik V vaccine, which is based on well-studied human adenoviral vector platform with proven safety, is undergoing clinical trials for the coronavirus pandemic.

Dr. Reddy's Laboratories is a pharmaceutical company. Through its three businesses - pharmaceutical services and active ingredients, global generics and proprietary products – the company offers a portfolio of products and services, including active pharmaceutical ingredients (API), custom pharmaceutical services (CPI), generics, biosimilars, differentiated formulations and new chemical entities.

The drug major's consolidated net profit skid 12.11% to Rs 594.60 crore on 14.93% jump in revenue from operations to Rs 4,417.50 crore in Q1 June 2020 over Q1 June 2019.

18-Sep-2020  Natco Pharma Ltd leads gainers in 'A' group
Natco Pharma Ltd leads gainers in 'A' group

Sudarshan Chemical Industries Ltd, Dr Reddys Laboratories Ltd, Cipla Ltd and Lupin Ltd are among the other gainers in the BSE's 'A' group today, 18 September 2020.

Natco Pharma Ltd surged 19.99% to Rs 931.7 at 11:54 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 3.54 lakh shares were traded on the counter so far as against the average daily volumes of 17395 shares in the past one month.

Sudarshan Chemical Industries Ltd soared 8.89% to Rs 532. The stock was the second biggest gainer in 'A' group. On the BSE, 72202 shares were traded on the counter so far as against the average daily volumes of 74515 shares in the past one month.

Dr Reddys Laboratories Ltd spiked 8.83% to Rs 5252.55. The stock was the third biggest gainer in 'A' group. On the BSE, 2.62 lakh shares were traded on the counter so far as against the average daily volumes of 46517 shares in the past one month.

Cipla Ltd jumped 7.53% to Rs 808.65. The stock was the fourth biggest gainer in 'A' group. On the BSE, 8.16 lakh shares were traded on the counter so far as against the average daily volumes of 2.31 lakh shares in the past one month.

Lupin Ltd rose 7.30% to Rs 1113.75. The stock was the fifth biggest gainer in 'A' group. On the BSE, 2.94 lakh shares were traded on the counter so far as against the average daily volumes of 1.31 lakh shares in the past one month.

18-Sep-2020  Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited -...
Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Press Release

Dr. Reddys Laboratories Limited has informed the Exchange regarding a press release dated September 17, 2020, titled 'Dr. Reddys Laboratories announces settlement of U.S. Revlimid« (lenalidomide) Capsules patent litigation with Celgene, a Bristol Myers Squibb Company'.
17-Sep-2020  Dr Reddys Laboratories forays into OTC eye care space
Dr Reddys Laboratories forays into OTC eye care space

Dr Reddys Laboratories announced the launch of over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the storebrand equivalents of Pataday® Once Daily Relief and Pataday® Twice Daily Relief, in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA).

Dr. Reddy's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1% are indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander. The Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% is also indicated for the temporary relief of red eyes.

Dr. Reddy's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% is available in a 2.5 mL bottle and Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% is available in a 5 mL bottle size.

Pataday® is a registered trademark of Novartis AG.

17-Sep-2020  Dr Reddys Laboratories Ltd soars 2.77%, up for third straight...
Dr Reddys Laboratories Ltd soars 2.77%, up for third straight session

Dr Reddys Laboratories Ltd rose for a third straight session today. The stock is quoting at Rs 4756.25, up 2.77% on the day as on 12:54 IST on the NSE. The benchmark NIFTY is down around 0.58% on the day, quoting at 11537.8. The Sensex is at 39101.77, down 0.51%. Dr Reddys Laboratories Ltd has added around 5.22% in last one month.

Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has added around 1.1% in last one month and is currently quoting at 11688.55, up 0.17% on the day. The volume in the stock stood at 53.13 lakh shares today, compared to the daily average of 10.69 lakh shares in last one month.

The benchmark September futures contract for the stock is quoting at Rs 4763, up 2.68% on the day. Dr Reddys Laboratories Ltd is up 73.35% in last one year as compared to a 6.43% gain in NIFTY and a 47.77% gain in the Nifty Pharma index.

The PE of the stock is 23.06 based on TTM earnings ending June 20.

17-Sep-2020  Dr Reddys settles patent litigation with Celgene for REVLIMID®...
Dr Reddys settles patent litigation with Celgene for REVLIMID® (lenalidomide) capsules

Dr Reddys Laboratories announced the settlement of their litigation with Celgene, a wholly owned subsidiary of Bristol Myers Squibb, relating to patents for REVLIMID® (lenalidomide) capsules.

In settlement of all outstanding claims in the litigation, Celgene has agreed to provide Dr Reddy's with a license to sell volume-limited amounts of generic lenalidomide capsules in the U.S. beginning on a confidential date after March 2022 subject to regulatory approval. The agreed-upon percentages are confidential. Dr. Reddy's is also licensed to sell generic lenalidomide capsules in the U.S. without volume limitations beginning on 31 January 2026.

Incorporation Year 1984 
Registered Office 8-2-337 Road No 3,Banjara Hills,
Hyderabad,
Telangana-500034
Telephone 91-40-49002900 
Fax 91-40-49002999 
Chairman K Satish Reddy
Managing Director NA
Company Secretary Sandeep Poddar 
Auditor S R Batliboi & Associates LLP 
Face Value(Rs)
Market Lot
Listing BSE,MSEI,New York,NSE 
Registrar Big Share Services Pvt Ltd
3rd Flr 306 Rightwin,Amrutha Ville,Somajiguda,Hyderabad-500082 
Toll Free number: 1800-425-5501 / 1800-103-5501
FINANCIAL TOOLS